Efficacy and safety of a 3-month dosing regimen of degarelix in Japanese patients with prostate cancer: a phase II maintenance-dose-finding study

The 3-month dosing regimen of degarelix with maintenance doses of 360 and 480 mg was effective and safe for the treatment of Japanese patients with prostate cancer.

[1]  Joel T Dudley,et al.  Androgen Deprivation Therapy and Future Alzheimer's Disease Risk. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  T. Choueiri,et al.  Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy: Effects of Androgen-Deprivation Therapy. , 2016, JAMA oncology.

[3]  Kazuto Ito,et al.  Clinical endocrinological evaluation of the gonadal axis (testosterone, LH and FSH) in prostate cancer patients switched from a GnRH antagonist to a LHRH agonist , 2015, Basic and Clinical Andrology.

[4]  D. Siemens,et al.  Serum follicle-stimulating hormone levels predict time to development of castration-resistant prostate cancer. , 2015, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[5]  X. Maldonado,et al.  Androgen deprivation and radiotherapy in patients with prostate cancer and cardiovascular risk factors: clinical controversies , 2015, Clinical and Translational Oncology.

[6]  F. Saad,et al.  The impact of androgen‐deprivation therapy (ADT) on the risk of cardiovascular (CV) events in patients with non‐metastatic prostate cancer: a population‐based study , 2014, BJU international.

[7]  B. Tombal,et al.  Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. , 2014, European urology.

[8]  S. Horie,et al.  Serum level of follicle-stimulating hormone is associated with extraprostatic extension of prostate cancer , 2013, Prostate international.

[9]  E. Crawford,et al.  New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists , 2012, Prostate Cancer and Prostatic Diseases.

[10]  T. Tammela,et al.  The effect of baseline testosterone on the efficacy of degarelix and leuprolide: further insights from a 12-month, comparative, phase III study in prostate cancer patients. , 2012, Urology.

[11]  Y. Ohashi,et al.  The efficacy and safety of degarelix, a GnRH antagonist: a 12-month, multicentre, randomized, maintenance dose-finding phase II study in Japanese patients with prostate cancer. , 2012, Japanese journal of clinical oncology.

[12]  B. Persson,et al.  An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer , 2011, Therapeutic advances in urology.

[13]  E. Crawford,et al.  Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics. , 2010, European urology.

[14]  F. Schröder,et al.  The efficacy and safety of degarelix: a 12‐month, comparative, randomized, open‐label, parallel‐group phase III study in patients with prostate cancer , 2008, BJU international.

[15]  H. Akaza,et al.  [Clinical effects of a 3-month formulation LH-RH agonist (Zoladex LA 10.8 mg depot) in patients with prostate cancer]. , 2001, Hinyokika kiyo. Acta urologica Japonica.

[16]  Z-Q Tao,et al.  Epidemiology of prostate cancer: current status. , 2015, European review for medical and pharmacological sciences.

[17]  Tao Zq,et al.  Epidemiology of prostate cancer: current status. , 2015 .

[18]  E. Crawford,et al.  Adverse events associated with hormonal therapy for prostate cancer. , 2005, Reviews in urology.

[19]  Kazuto Ito,et al.  [Clinical effects of a 3-month formulation LH-RH agonist, TAP-144-SR (3M) in prostate cancer patients]. , 2002, Hinyokika kiyo. Acta urologica Japonica.